Scientists Develop Technology To Detect Lung Cancer, University of Liverpool, UK
Main Category: Lung CancerArticle Date: 20 Apr 2005 - 12:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Researchers at the University of Liverpool have developed a breakthrough technology that identifies molecular markers in early lung cancer.
The new technology, created in collaboration with SEQUENOM, developers of genetic analysis products, and Methexis Genomics, uses a DNA analysis technique called methylation profiling to detect cells in the lung that are likely to become cancerous.
There are a number of genetic mechanisms that can alter the characteristics of a normal cell and change it into a cancer cell. One of these mechanisms is methylation, which causes a change in the DNA structure of particular genes and results in altering its control - this may switch the gene on or off at the wrong time in the cell cycle.
Dr Lakis Liloglou, Head of the University's Lung Cancer Molecular Biomarkers Group, explains: "This is of particular importance in lung cancer research, as the changes in methylation status of the DNA are considered to be a marker for early disease detection.
"Even though DNA methylation analysis has been a previous area of research, prior techniques had a range of technical limitations, that prevented them from being of any real clinical use. This newly developed method overcomes many of the problems and combines the sensitivity of high-powered microscopes with the capability of analysing many samples at a time."
As part of their research to develop the new technology, the team, based at the University of Liverpool Cancer Research Centre, analysed the methylation profile of 47 genes in lung specimens from 48 patients with a history of smoking. The genes that were selected were known to be involved in cancer development and in this study they were able to accurately determine the relationship between gene methylation in normal and tumour tissue, which in the long term will be of enormous value in identifying high risk individuals.
Professor John Field, Director of the Roy Castle Lung Cancer Research Programme, said: "Early detection of lung cancer is the prime objective of our research programme. This depends on the identification of early biomarkers in patients who are at risk of developing the disease prior to clinical symptoms."
"The partnership between the University and Sequenom has provided a breakthrough in our goal to detect early genetic changes in individuals who are at the highest risk."
The research is being presented this week at the 96th annual meeting of the American Association for Cancer Research (AACR) in Anaheim, California.
1 The University of Liverpool is one of the UK's leading research institutions with a prodigious spread of expertise - from the humanities and social sciences to engineering, science, veterinary science and medicine. It attracts collaborative and contract research commissions from a wide range of national and international organisations - commissions valued at more than Ł80 million annually.
2 SEQUENOM is committed to providing the best genetic analysis products that translate genomic science into superior solutions for biomedical research, molecular medicine and agricultural applications.
3 Methexis Genomics NV is a Ghent, Belgium-based genomics company dedicated to the development of proprietary technologies for improving the efficiency and reducing the cost of genetic variation analysis in human health and agriculture applications.
4 Dr Liloglou's post is funded by the Roy Castle Lung Cancer Foundation. The charity is the only one in the world wholly dedicated to research into the early detection of lung cancer. The Foundation also offers patient support, advocacy and information network and operates a very successful smoking cessation service.
For further information:
Kate Spark, Media Relations Manager
Tel: 0151 794 2247, Mobile: 07970 247391, E-mail: kate.spark@liv.ac.uk
Joanna Robotham, Press Officer
Tel: 0151 794 2026, Mobile: 07970 247396, E-mail: joanna.robotham@liv.ac.uk
Samantha Martin, Assistant Press Officer
Tel: 0151 794 2248, Mobile: 07970 247836, E-mail: samantha.martin@liv.ac.uk
http://www.liv.ac.uk
Visit our lung cancer section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/23160.php>
APA
http://www.medicalnewstoday.com/releases/23160.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




